Cdmo survey report of global pharmaceutical industry in 2022 From PricewaterhouseCoopers
The following is the Cdmo survey report of global pharmaceutical industry in 2022 From PricewaterhouseCoopers recommended by recordtrend.com. And this article belongs to the classification: PricewaterhouseCoopers, research report.
The global covid-19 pandemic, geopolitical tensions and trade restrictions have attracted attention to changes in the pharmaceutical supply chain. Treatment is increasingly done by competent contract development and manufacturing organizations. The emergence of new and very complex advanced therapies (ATX) complements the traditional macromolecular and small molecule therapies, and this trend will deepen and accelerate. Cdmo whole process contract R & D and production organization refers to customization, R & D and production in the medical field. It is a new R & D outsourcing mode in the medical field.
Main findings
1. Mah is expanding its strategic cooperation with cdmo
Having a number of strategic cdmo partners can provide MAH with advantages, improve capability and agility, and share the cost of developing and manufacturing products. Therefore, MAH finds it increasingly important to establish strategic cooperation.
2. Cdmo management is becoming more and more professional to ensure common success
In order to lay the foundation for successful long-term cooperation and establish competitive advantages, MAH needs personal resources to contact cdmo and is supported by an internal cross functional expert team.
3. Mah is increasingly acting as a cdmo, providing spare capacity for the market to absorb costs
Providing cdmo services brings MAH many advantages: obtaining additional revenue with potentially higher profits, the number of contracts, better cost absorption and stable production.
4. Cdmo continues to expand its service portfolio to end-to-end service providers
In order to distinguish from competitors, more and more cdmo are becoming full-service providers, a large part of which provide end-to-end services from development to packaging, supplemented by additional service management such as supervision, analysis or projects.
5. Cdmo is surpassing traditional technology portfolio
In order to identify new growth opportunities and improve relevance, pure cdmo is expanding its product portfolio horizontally to include multiple modes, while most generic cdmo and pharmaceutical affiliated cdmo involve only one production technology.
6. Cdmo is producing advanced therapies
In order to gain a leading position in emerging markets, cdmo is building new capabilities and capabilities for advanced therapies. From 2021 to 2025, the compound annual growth rate of advanced therapies is 47%, while macromolecules and small molecules are 8% and 5% respectively.
If you want to get the full report, you can contact us by leaving us the comment. If you think the information here might be helpful to others, please actively share it. If you want others to see your attitude towards this report, please actively comment and discuss it. Please stay tuned to us, we will keep updating as much as possible to record future development trends.
RecordTrend.com is a website that focuses on future technologies, markets and user trends. We are responsible for collecting the latest research data, authority data, industry research and analysis reports. We are committed to becoming a data and report sharing platform for professionals and decision makers. We look forward to working with you to record the development trends of today’s economy, technology, industrial chain and business model.Welcome to follow, comment and bookmark us, and hope to share the future with you, and look forward to your success with our help.
